Bristol Myers Squibb (NYSE: BMY) today announced that the company will host a virtual Investor Event on Sunday, August 28, 2022, at 7:00 p.m. CET/ 1:00 p.m. ET to discuss data from the AXIOMATIC-SSP Phase 2 trial of milvexian in secondary stroke prevention presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain.
Company executives will provide an overview of data presented and address questions from investors and analysts.
Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005877/en/
Contacts
Bristol Myers Squibb
Media:
media@bms.com
Investor Relations:
investor.relations@bms.com
